GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Z

Zhejiang Hisun Pharmaceutical Co 600267.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

13.38

-0.15%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥10.55bn

FY2016FY2025

Net income

CN¥540.7m

FY2016FY2025

Free cash flow

CN¥1.66bn

FY2016FY2025

Shareholders' equity

CN¥8.61bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥10.55bnCN¥9.79bnCN¥10.37bnCN¥12.04bnCN¥12.14bnCN¥11.35bnCN¥11.07bnCN¥10.19bnCN¥10.57bnCN¥9.73bn
Research and developmentCN¥478.5mCN¥357.7mCN¥392.0mCN¥428.7mCN¥372.8mCN¥401.1mCN¥903.8mCN¥639.5mCN¥439.5mCN¥411.0m
Operating incomeCN¥1.28bnCN¥721.3mCN¥89.4mCN¥682.5mCN¥700.1mCN¥776.9mCN¥520.9m−CN¥103.0mCN¥248.9mCN¥12.2m
Net incomeCN¥540.7mCN¥601.2m−CN¥93.2mCN¥488.9mCN¥486.9mCN¥417.2mCN¥93.1m−CN¥492.5mCN¥13.6m−CN¥94.4m
Diluted earnings per share0.460.52-0.080.420.410.430.10-0.510.01-0.09

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥15.05bnCN¥15.97bnCN¥17.61bnCN¥18.78bnCN¥19.37bnCN¥20.86bnCN¥21.47bnCN¥21.85bnCN¥21.64bnCN¥20.76bn
Cash and short-term investments—CN¥1.50bnCN¥1.59bnCN¥1.40bnCN¥1.30bnCN¥2.06bnCN¥1.76bnCN¥1.89bnCN¥2.31bnCN¥2.69bn
Total liabilitiesCN¥6.20bnCN¥7.39bnCN¥9.26bnCN¥10.45bnCN¥12.03bnCN¥12.60bnCN¥13.78bnCN¥14.48bnCN¥13.76bnCN¥12.72bn
DebtCN¥155.0mCN¥3.23bnCN¥4.55bnCN¥6.13bnCN¥7.63bnCN¥8.17bnCN¥8.87bnCN¥10.73bnCN¥10.67bnCN¥10.14bn
Shareholders' equityCN¥8.61bnCN¥8.34bnCN¥8.10bnCN¥8.08bnCN¥7.30bnCN¥6.68bnCN¥6.27bnCN¥6.18bnCN¥6.72bnCN¥6.76bn
Shares outstanding1,163m1,156m1,159m1,158m1,196m961m966m966m933m1,066m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥2.03bnCN¥2.11bnCN¥1.52bnCN¥2.07bnCN¥1.74bnCN¥1.59bnCN¥698.4mCN¥1.45bnCN¥1.24bnCN¥775.9m
Capital spending−CN¥376.4m−CN¥238.4m−CN¥240.0m−CN¥530.6m−CN¥622.4m−CN¥692.0m−CN¥1.08bn−CN¥1.60bn−CN¥1.46bn−CN¥1.77bn
Free cash flowCN¥1.66bnCN¥1.88bnCN¥1.28bnCN¥1.54bnCN¥1.11bnCN¥897.6m−CN¥378.2m−CN¥154.7m−CN¥221.5m−CN¥991.0m
Dividends paid−CN¥343.4m−CN¥148.5m−CN¥199.2m−CN¥166.3m−CN¥58.0m−CN¥48.2m−CN¥499.3m−CN¥538.5m−CN¥524.3m−CN¥512.8m

Latest quarters

By quarter end

Sept 2026Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024
RevenueCN¥2.05bnCN¥2.09bnCN¥2.39bnCN¥2.63bnCN¥2.67bnCN¥2.62bnCN¥2.63bnCN¥1.91bn
Operating incomeCN¥576.3mCN¥416.0mCN¥363.0mCN¥301.8mCN¥230.9mCN¥169.0mCN¥250.5mCN¥114.9m
Net incomeCN¥509.2mCN¥280.8mCN¥355.7mCN¥79.8mCN¥161.9mCN¥104.8mCN¥194.2mCN¥85.9m
Diluted earnings per share0.440.240.310.070.140.090.170.07
Cash from operations————CN¥438.0mCN¥948.0mCN¥262.0m—
Capital spending−CN¥124.0m−CN¥90.0m−CN¥127.0m−CN¥161.0m−CN¥102.0m−CN¥63.0m−CN¥48.0m−CN¥122.0m
Free cash flow————CN¥336.0mCN¥885.0mCN¥214.0m—
Total assetsCN¥13.82bnCN¥13.57bnCN¥13.81bnCN¥15.05bnCN¥15.32bnCN¥15.56bnCN¥16.01bnCN¥15.97bn
Cash and short-term investments————CN¥1.52bnCN¥1.81bnCN¥1.59bnCN¥1.50bn
Debt——CN¥35.0mCN¥155.0mCN¥3.21bnCN¥2.73bnCN¥3.17bnCN¥3.17bn
Shareholders' equityCN¥9.51bnCN¥8.99bnCN¥8.95bnCN¥8.61bnCN¥8.51bnCN¥8.35bnCN¥8.54bnCN¥8.34bn

Financial ratios

Data as of 3 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin8.7%7.4%0.9%7.8%5.8%8.6%
Net margin5.1%6.1%-0.9%4.1%4.0%3.7%
Return on equity6.3%7.2%-1.1%6.1%6.7%6.2%
Return on assets3.6%3.8%-0.5%2.6%2.5%2.0%
Free cash flow yield17.6%17.3%12.9%19.1%16.8%20.2%
Revenue growth7.8%-5.7%-13.8%-0.8%6.9%2.6%
Earnings growth-10.1%-745.2%-119.1%0.4%16.7%348.2%
Current ratio0.93x0.92x0.97x0.90x0.72x0.70x
Debt to equity0.02x0.38x0.56x0.75x0.92x1.31x
Equity ratio57.2%52.2%46.0%43.0%37.7%32.0%
Interest coverage9.15x4.64x0.42x3.27x2.01x2.28x
R&D as a share of sales4.5%3.7%3.8%3.6%3.1%3.5%
Buybacks as a share of market value-0.6%0.3%-0.1%3.1%-24.5%0.5%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-4.3%-1.5%1.9%
Operating income23.4%10.5%35.8%
Net income3.4%5.3%44.6%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin9.8%6.5%6.4%4.3%
Net margin5.6%3.6%3.7%1.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings21.316.0-116.526.134.438.1102.8-16.5—-148.6
Price to sales1.11.01.11.11.41.40.90.81.31.4

Dividends and splits

Per share, in the currency the company pays

Paid for 1 years. Last went ex-dividend on 16 Jun 2026.

FY2026FY2025FY2023FY2022FY2021FY2020FY2018FY2017
Paid in the year0.210.210.170.140.050.050.050.05
  • 8-for-5 split · 25 May 2012
  • 1-to-1 reverse split · 16 Feb 2006
  • 9-for-5 split · 29 Sept 2004
  • 8-for-5 split · 24 May 2001

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.